Considered and approved the unaudited financial results of the Company for quarter ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Prevest Denpro Ltd reported strong year-on-year growth for the quarter ended December 31, 2025. Standalone revenue from operations rose about 23% to ₹1,837.46 lakhs versus ₹1,492.62 lakhs in the same quarter last year, with total income at ₹1,953.44 lakhs. Net profit grew to ₹515.07 lakhs (from ₹446.37 lakhs), translating to an EPS of ₹4.29 (vs ₹3.72 YoY). For the nine-month period, standalone revenue grew to ₹5,276.02 lakhs and net profit to ₹1,535.45 lakhs. Consolidated figures (including subsidiary Denvisio Biomed Limited) were broadly in line, with Q3 net profit at ₹472.09 lakhs and nine-month net profit at ₹1,466.91 lakhs. Statutory auditor Mittal & Associates issued a clean limited review report with no qualifications, and management confirmed no material impact from the new Labour Codes.
Solid double-digit revenue growth, steady profit expansion, and an unqualified auditor review are positive signals for shareholders, suggesting healthy operational momentum. The slight quarter-on-quarter dip in revenue and profit versus Q2 FY26 is worth watching but is not a concern given the strong YoY trajectory.